Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

PURPOSE: Activating KIT mutations are part of the pathogenesis of systemic mastocytosis (SM). Nilotinib is a tyrosine kinase inhibitor that potently inhibits activated forms of KIT. This phase 2, open-label, single-arm study (CAMN107A2101; www.clinicaltrials.gov NCT00109707) evaluated nilotinib in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochhaus, Andreas, Baccarani, Michele, Giles, Francis J., le Coutre, Philipp D., Müller, Martin C., Reiter, Andreas, Santanastasio, Helene, Leung, Mimi, Novick, Steven, Kantarjian, Hagop M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768228/
https://www.ncbi.nlm.nih.gov/pubmed/26002753
http://dx.doi.org/10.1007/s00432-015-1988-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768228/
https://www.ncbi.nlm.nih.gov/pubmed/26002753
http://dx.doi.org/10.1007/s00432-015-1988-0

Ejemplares similares